SAB Biotherapeutics, Inc.
$3.86
▲
0.26%
2026-04-21 09:16:01
www.sab.bio
NCM: SABS
Explore SAB Biotherapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$196.16 M
Current Price
$3.86
52W High / Low
$6.6 / $1.3
Stock P/E
14.78
Book Value
$3.18
Dividend Yield
—
ROCE
-30.19%
ROE
14.96%
Face Value
—
EPS
$-0.79
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
86
Beta
0.61
Debt / Equity
3.93
Current Ratio
9.46
Quick Ratio
9.46
Forward P/E
-11.36
Price / Sales
—
Enterprise Value
$100.42 M
EV / EBITDA
-2.19
EV / Revenue
—
Rating
None
Target Price
$9.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Day One Biopharmaceuticals, Inc. | $21.48 | — | $2.22 B | — | -28.56% | -22.74% | $21.49 / $5.63 | $4.28 |
| 2. | Pulmatrix, Inc. | $1.34 | — | $4.91 M | — | -135.67% | -80.93% | $9.37 / $1.16 | $1.04 |
| 3. | Adaptive Biotechnologies Corporation | $14.58 | — | $2.23 B | — | -13.51% | -27.82% | $20.76 / $6.77 | $1.42 |
| 4. | Immunovant, Inc. | $28.53 | — | $5.81 B | — | -61.93% | -69.35% | $29.48 / $13.36 | $4.85 |
| 5. | Nautilus Biotechnology, Inc. | $2.96 | — | $383.49 M | — | -36.49% | -32.27% | $4.31 / $0.62 | $1.24 |
| 6. | Celcuity Inc. | $120.09 | — | $5.8 B | — | -40.76% | -1.64% | $127.34 / $9.5 | $2.08 |
| 7. | Ocular Therapeutix, Inc. | $9.52 | — | $2.09 B | — | -35.66% | -54.85% | $16.44 / $6.23 | $3.03 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -15.77 M | -12.68 M | -9.73 M | -10.77 M | -10.01 M | — |
| Net Profit | -16.86 M | 45.45 M | -10.11 M | -5.2 M | -11.39 M | — |
| EPS in Rs | -0.24 | 0.65 | -0.14 | -0.07 | -0.16 | -1.12 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -48.95 M | -42.91 M | -38.08 M | -28.92 M |
| Net Profit | 13.27 M | -34.11 M | -42.19 M | -18.74 M |
| EPS in Rs | 0.19 | -0.49 | -0.6 | -0.27 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 172.81 M | 44.2 M | 83.94 M | 50.9 M |
| Total Liabilities | 21.32 M | 18.23 M | 26.64 M | 19.85 M |
| Equity | 151.49 M | 25.97 M | 57.3 M | 31.06 M |
| Current Assets | 101.05 M | 23.79 M | 58.91 M | 22.1 M |
| Current Liabilities | 10.68 M | 7.98 M | 10.81 M | 14.99 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -44.78 M | -34.29 M | -25.12 M | -23.46 M |
| Investing CF | -121.71 M | -11.96 M | -0.15 M | -2.09 M |
| Financing CF | 168.3 M | -1.17 M | 66.77 M | 1.05 M |
| Free CF | -45.71 M | -34.63 M | -25.32 M | -25.63 M |
| Capex | -0.93 M | -0.34 M | -0.2 M | -2.17 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 19.17% | -125.14% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-01-05 | 1:0.1 |